Overview

Safety and Tolerability of SYNB1020-CP-001

Status:
Completed
Trial end date:
2018-04-11
Target enrollment:
Participant gender:
Summary
A Phase 1, First-in-human, Oral Single and Multiple Dose-Escalation, Randomized, Double-blinded, Placebo-controlled Study of SYNB1020 in Healthy Adult Volunteers to Evaluate Safety, Tolerability, Dosing, and Pharmacodynamics
Phase:
Phase 1
Details
Lead Sponsor:
Synlogic